Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Siegfried
Siegfried
Activities:
Manufacturing
Ingredients
Regulatory
Research & Development
Cleaning
X
LinkedIn
Trending Articles
IMPACT CKD model reveals the escalating toll of chronic kidney disease
The model projects up to 125 million of the population across eight countries to suffer from chronic kidney disease by 2032
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Isospec Analytics launches biomolecular analysis technology to identify unknown molecules
The novel technology optimises the identification process of unknown molecules compared to mass analysis
Building strong foundations for a resilient and planet-friendly future
Having recently released its inaugural environmental, social and governance (ESG) report, Dr Kevin Robinson caught up with Gigi Bat-Erdene, Global ESG Program Manager at PCI...
ten23 health and Ypsomed collaborate to commercialise the YpsoDose patch injector
The partnership will bring the drug delivery device to the pharmaceutical market quicker, whilst reducing development risks
Upcoming event
Making Pharmaceuticals
23–24 April 2024 | Exhibition | Coventry, UK
See all
Related Content
Manufacturing
Swiss biomanufacturing sector continues to thrive in 2023
Seigfried, Lonza, ten23 health, Bachem and Dottikon all announce major expansions
Manufacturing
DiNAQOR agrees acquisition to commercialise CGT development and manufacturing platform
Siegfried has made a total investment for the majority acquisition of CDMO DiNAMIQS and the establishment of the new GMP facility that will be in the mid-double-digit millions Swiss Francs
You need to be a subscriber to read this article.
Click here
to find out more.
Manufacturing
Optimising scale-up with flow process technologies
Speed of synthesis is of the essence when medicinal chemists invent new molecules, reports Sarah Houlton
Design & Build
Siegfried acquires three BASF sites
Acquisition represents the final step in Siegfried’s targeted 5-year procurement policy
Media
Siegfried Group sells biologics division
<p>The Siegfried Group, based in Zofingen in Switzerland, is selling its biotechnology business unit to an Indian company, Avesta Biotherapeutics and Research (ABRPL), for an undisclosed sum. </p>
Sharp increase in profits at Siegfried Group
Swiss pharmaceutical company The Siegfried Group has reported its best financial results in its 130-year history.
Subscribe now